1. Regeneron faces a class action due to misleading business practices. 2. Allegations include undisclosed credit card fees affecting Eylea pricing. 3. Misreporting of prices reportedly violated the False Claims Act. 4. Investors experienced losses when the misleading information was revealed. 5. Shareholders can apply to be lead plaintiff until March 4, 2025.
The class action indicates potential legal and financial liabilities that can harm REGN's stock price, similar to past cases involving biotechnology firms facing legal issues.
The article discusses serious allegations that could lead to significant financial impacts, influencing REGN's stock.
Immediate investor sentiment may react negatively, as seen in past stock drops following negative news.
Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and October 30, 2024. Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
Robbins LLP is Investigating Allegations that Regeneron Pharmaceuticals, Inc. (REGN) Misled Investors Regarding its Business Prospects
According to the complaint, during the class period, defendants failed to disclose: (1) that Regeneron paid credit card fees to distributors on the condition that distributors did not charge Eylea customers more to use a credit card; (2) that these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) that, as a result, Regeneron offered a price concession that lowered Eylea's selling price; (4) that, because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron's price concessions provided a competitive advantage; (5) that, as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) that, by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the truth was revealed, the price of Regeneron's stock fell, harming investors.
You may be eligible to participate in the class action against Regeneron Pharmaceuticals, Inc. Shareholders who want to serve as lead plaintiff for the class must submit their application to the court by March 4, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Regeneron Pharmaceuticals, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Robbins LLP